Sleep disorders afflict vast populations globally, manifesting in diverse forms such as chronic insomnia, obstructive sleep apnea, and circadian rhythm disruptions. These conditions exact a profound toll on physiological health, cognitive capacity, and emotional resilience. Historically, sleep research has prioritized central nervous system mechanisms; however, this landmark review underscores the critical influence of peripheral systems, particularly gut microbiota, in modulating brain function and behavior. The convergence of microbiome science with sleep physiology heralds a transformative era whereby digestive ecosystems are recognized as active contributors to sleep regulation rather than passive participants.

The gut microbiome—comprising an immense and dynamic population of bacteria, viruses, and fungi—engages in continuous bidirectional communication with the brain via neural, immune, and endocrine routes. Central among these is the vagus nerve, which enables rapid neuronal crosstalk, while circulating immune factors and microbial metabolites serve as systemic messengers capable of traversing the blood-brain barrier. Professor Lu emphasizes that aberrations in microbial community structure, or dysbiosis, consistently correlate with sleep disruptions, suggesting that altered gut ecology is both a marker and a mediator of sleep pathology.

Human clinical investigations alongside controlled animal studies reveal compelling patterns: individuals suffering from chronic insomnia exhibit markedly reduced microbial diversity and deficits in bacterial families known for beneficial metabolic functions. Similarly, patients diagnosed with obstructive sleep apnea display diminished alpha-diversity, with microbial signatures correlating directly with disease severity measures such as apnea-hypopnea indices and oxygen saturation. These findings not only establish a robust associative framework but also hint at mechanistic underpinnings.

At the molecular interface of gut-brain communication, microbial metabolites emerge as critical modulators. Short-chain fatty acids (SCFAs), particularly butyrate, synthesized by bacterial fermentation of dietary fibers, demonstrate neuroprotective and anti-inflammatory properties that preserve sleep integrity. Empirical data from clinical trials suggest that butyrate supplementation enhances sleep quality in inflammatory bowel disease patients, while animal experiments confirm its capacity to attenuate inflammation and cognitive deficits induced by sleep deprivation. Altered bile acid profiles further delineate gut microbiome involvement, with chronic insomnia linked to elevated primary bile acids and depleted secondary bile acids, implicating a dysregulated microbiota-bile acid axis that may exacerbate cardiometabolic comorbidities associated with poor sleep.

The production of neurotransmitters by gut microbes elucidates additional pathways of influence. Select strains of Lactobacillus and Bifidobacterium harbor genes responsible for generating gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter central to sleep initiation and maintenance. Electroencephalographic evidence corroborates that both endogenous and exogenous GABA can modulate cortical activity, reinforcing the gut’s neurochemical impact. Moreover, the gut is the predominant extraneural site of serotonin synthesis, with more than 90% of the body’s serotonin produced within the intestinal tract. Serotonin’s rhythmic fluctuations align with sleep-wake cycles, and disturbances in its metabolism—linked to gut microbiota alterations—may precipitate circadian misalignment and sleep deficits. The gastrointestinal tract also paradoxically serves as a major melatonin reservoir, with concentrations vastly exceeding plasma levels, further emphasizing the gut’s centrality in circadian biology.

Delineating the microbial landscapes characteristic of specific sleep disorders, the review synthesizes extensive data sets revealing both unique and overlapping microbial taxonomic shifts. Chronic insomnia studies involving thousands have documented consistent declines in Ruminococcaceae species, bacterial groups implicated in bile acid metabolism and systemic inflammation. Obstructive sleep apnea research echoes this narrative, where diminished levels of these commensals associate with hypoxia-induced gut inflammation. Investigations into circadian disruption conditions, especially in shift workers, reveal compositional microbiota oscillations tied to altered metabolic pathways that favor glucose intolerance, signifying a link between microbiota and metabolic sequelae of sleep loss. Likewise, rarer disorders such as narcolepsy and REM sleep behavior disorder exhibit discrete microbial signatures, some predictive of neurodegenerative progression, offering novel biomarker avenues.

Sleep disturbances frequently co-occur with neuropsychiatric disorders, including major depressive disorder, anxiety, autism spectrum disorder, and Parkinson’s disease. The review highlights commensurate shifts in gut microbial genera like Blautia, Coprococcus, and Dorea correlating with sleep parameters in depression, as well as decreased Faecalibacterium and Agathobacter in autistic children with sleep impairments. Parkinson’s disease subtypes characterized by early sleep disturbances similarly demonstrate gut dysbiosis, marked by elevated Escherichia coli and Akkermansia muciniphila alongside diminished SCFA producers, underscoring shared pathogenic routes.

Translating mechanistic elucidations into therapeutic potentials, the review appraises emerging microbiota-targeted interventions. Probiotic administration manifests tangible improvements in sleep metrics across chronic insomnia, Parkinson’s disease, and substance use disorders, with strains such as Lactobacillus plantarum PS128 and Bifidobacterium breve CCFM1025 demonstrating modulation of neurophysiological markers including delta power during deep sleep and attenuation of hypothalamic-pituitary-adrenal axis hyperactivity. Complementary animal research substantiates these findings, noting enhancements in non-rapid eye movement sleep duration and reductions in anxiety-like behaviors consequent to probiotic supplementation.

Prebiotics—nondigestible fibers fostering beneficial microbial growth—also show promise in ameliorating sleep disruptions, particularly those induced by circadian misalignment and metabolic disorders. Clinical trials affirm that compounds like partially hydrolyzed guar gum and resistant dextrin improve sleep quality scores, while animal studies suggest mechanisms involving bile acid metabolism and gut barrier integrity. Synbiotics, combining both probiotics and prebiotics, offer synergistic effects, exhibiting notable efficacy in post-acute COVID-19 syndrome and other sleep-compromised populations, enhancing subjective sleep quality and physiological markers in randomized controlled settings.

Fecal microbiota transplantation (FMT) represents a potent, albeit complex, therapeutic frontier. Clinical interventions deploying FMT in chronic insomnia patients with comorbidities have yielded remarkable augmentations in sleep quality and symptom alleviation, accompanied by favorable shifts in gut bacterial populations. Similar benefits extend to fibromyalgia and pediatric autism sufferers, signaling FMT’s expansive potential. Nonetheless, practical constraints—stringent donor screening, procedural standardization, regulatory hurdles—currently restrict widespread FMT application to research contexts and select refractory cases.

This comprehensive synthesis proposes an integrated research framework designed to propel the field forward. The authors advocate a tiered approach beginning with multimodal phenotyping, incorporating neuroimaging modalities alongside robust microbiome and metabolomic profiling. Subsequent tiers focus on biomarker discovery through machine learning-driven multi-omic integration, causal inference employing germ-free animal models and longitudinal human trials, and the rigorous evaluation of microbiota-directed interventions through carefully controlled clinical studies. Harmonization of methodologies and standardization of biomarkers are emphasized as critical to advancing translatability and reproducibility.

Despite promising advancements, the review acknowledges persistent challenges, including interindividual variability in microbiota compositions and responses to interventions, methodological discrepancies across studies, and incomplete long-term safety data for microbiome-targeted therapies. Prioritizing well-powered, standardized clinical trials—particularly targeting conditions with robust microbiome-sleep mechanistic links like chronic insomnia and obstructive sleep apnea—will be imperative. Additionally, elucidating personalized microbial signatures and tailoring interventions accordingly offers an exciting horizon in precision medicine for sleep disorders.

In conclusion, this landmark review firmly establishes the microbiota-gut-brain axis as a central regulator in the complex architecture of sleep physiology and pathology. The identification of shared microbial alterations across a spectrum of sleep disorders accentuates the gut microbiome’s dual roles as both consequence and catalyst of sleep dysfunction. By bridging gaps across disciplines, this work lays a robust foundation for microbiota-based diagnostics and therapeutics, with the potential to revolutionize management strategies for sleep disorders globally. As the nexus of microbiology, neuroscience, and clinical medicine strengthens, the vision of harnessing gut microbiota to restore healthy sleep and enhance brain function draws ever closer to reality.

Subject of Research: People
Article Title: Brain-gut-microbiota interactions in sleep disorders
News Publication Date: 4 November 2025
Web References: https://doi.org/10.61373/bm025i.0128
References: The review article published in Brain Medicine supported by STI2030-Major Projects and the National Natural Science Foundation of China
Image Credits: Lin Lu
Keywords: microbiota-gut-brain axis, sleep disorders, gut microbiome, chronic insomnia, obstructive sleep apnea, circadian rhythm, short-chain fatty acids, bile acids, neurotransmitters, probiotics, fecal microbiota transplantation, sleep regulation

Parkinson’s disease (PD), a debilitating neurodegenerative disorder characterized primarily by motor dysfunction, tremors, and rigidity, has traditionally been studied through the prism of dopaminergic neuron degeneration and α-synuclein aggregation. However, emerging evidence from multidisciplinary research suggests that circadian dysregulation might not simply be a comorbid condition but rather a contributing mechanistic factor that exacerbates neuronal vulnerability. This paradigm shift opens new avenues for therapeutic intervention by targeting circadian rhythms to alleviate symptoms and possibly slow disease progression.

At the molecular level, the circadian clock is governed by a transcriptional-translational feedback loop involving core clock genes such as CLOCK, BMAL1, PER, and CRY. These genes oscillate with a near 24-hour rhythm, dictating downstream gene expression patterns essential for maintaining cellular homeostasis. In PD, studies reveal an aberrant expression of these clock genes, suggesting that dysfunction within these fundamental regulatory pathways compromises neuronal integrity. Notably, dysregulation in the expression of BMAL1 and PER2 has been implicated in reduced antioxidant response and elevated neuroinflammation, factors that are instrumental in dopaminergic neuron loss.

Beyond genetic expression, circadian clock dysfunction manifests clinically as disrupted sleep-wake cycles, fragmented sleep, and altered hormone secretion patterns in Parkinson’s patients. Sleep disturbances, which include rapid eye movement (REM) sleep behavior disorder and excessive daytime sleepiness, often precede motor symptoms, indicating that circadian perturbations may be an early biomarker of disease onset. The reciprocal relationship between sleep architecture abnormalities and neurodegeneration underscores the clock’s role not merely as a symptom but as a mechanistic driver in PD pathology.

Circadian misalignment also affects mitochondrial function and cellular energetics, processes critically compromised in Parkinson’s disease. The circadian clock regulates mitochondrial dynamics, biogenesis, and mitophagy, which are essential for neuronal survival. Disruption of clock genes can lead to mitochondrial dysfunction, increased oxidative stress, and impaired ATP production, cascading into neuronal demise. Experimental models demonstrate that clock gene mutations induce mitochondrial defects and exacerbate α-synuclein pathology, illustrating a pathogenic feedback loop linking circadian dysregulation with neurodegeneration.

The immune system, tightly intertwined with circadian rhythms, also plays a pivotal role in Parkinson’s disease progression. Microglial activation and neuroinflammation are hallmark features of PD, and these processes are rhythmically controlled by the circadian clock. Circadian dysfunction may therefore provoke sustained inflammatory states by deregulating cytokine production cycles, fostering an environment conducive to neuronal injury. Animal models with disrupted clock genes show heightened inflammatory responses correlating with accelerated neurodegeneration, emphasizing the importance of temporal regulation in immune homeostasis.

Therapeutically, the recognition of circadian disruption in Parkinson’s disease opens unprecedented strategic possibilities. Chronotherapy—aligning the timing of medication administration with the patient’s circadian rhythms—has demonstrated enhanced efficacy and reduced side effects in managing PD symptoms. Furthermore, interventions aimed at restoring circadian function, such as light therapy, melatonin supplementation, and lifestyle modifications including timed exercise and feeding schedules, show promise in improving sleep quality and motor symptoms, suggesting that reinforcing circadian rhythmicity may have disease-modifying potential.

Additionally, the development of pharmacological agents targeting core clock components or downstream circadian-regulated pathways is an exciting frontier. Small molecules capable of modulating clock gene expression or enhancing circadian amplitude could counteract the deleterious effects of clock dysfunction. Early-phase clinical trials investigating these agents in neurodegenerative conditions report encouraging outcomes, stimulating optimism that future treatments might integrate circadian biology as a core therapeutic principle.

Crucially, advances in wearable technology and digital biomarkers now enable continuous monitoring of circadian parameters such as motor activity patterns, sleep phases, and hormonal fluctuations in real-world settings. These tools allow the precise characterization of circadian disturbances in Parkinson’s patients and facilitate personalized therapeutic regimens. The integration of this data with molecular profiling could transform clinical management, moving towards precision medicine approaches that tailor interventions based on individual circadian phenotypes.

The unraveling of the circadian clock’s involvement in Parkinson’s disease also offers broader insights into neurodegeneration. Since circadian dysfunction is common across multiple neurodegenerative disorders, understanding its specific mechanisms in PD may elucidate universal pathways amenable to targeting across diseases. Moreover, circadian biology intersects with aging processes, and given that age is the primary risk factor for Parkinson’s, delineating how clock deterioration contributes to neuronal aging is paramount.

In sum, the convergence of circadian biology and Parkinson’s disease research represents a paradigm shift with vast therapeutic implications. By recognizing the circadian clock not merely as an epiphenomenon but as a central player in disease mechanisms, researchers are uncovering novel targets and strategies that promise to revolutionize patient care. The intricate dance between cellular timekeeping and neurodegeneration is only beginning to be understood, but its elucidation holds the key to unlocking more effective, holistic treatments for Parkinson’s disease.

Future research efforts must focus on comprehensive mapping of circadian alterations at genetic, molecular, systemic, and behavioral levels in Parkinson’s populations. Longitudinal studies tracking circadian integrity from prodromal to advanced disease stages are essential to clarify causality and timing of interventions. Moreover, interdisciplinary collaborations bridging chronobiology, neurology, immunology, and mitochondrial research are critical for developing integrated models of disease pathogenesis.

The therapeutic potential of targeting circadian dysfunction in Parkinson’s disease is underscored by preliminary clinical successes and mechanistic insights. Incorporating circadian principles into drug development pipelines and clinical protocols could enhance treatment efficacy and improve quality of life for millions affected by this devastating disorder. As scientific understanding deepens, the future promises innovative chronomedicine approaches that harness the power of our internal clocks to combat neurodegeneration.

The work spearheaded by researchers such as Yalçin, Grande, Outeiro, and collaborators has cemented this emerging field, providing a comprehensive framework that integrates circadian biology with Parkinson’s pathophysiology. Their synthesis of molecular mechanisms, clinical manifestations, and therapeutic avenues establishes a new foundation for translational research aimed at circadian restoration as a viable and potent strategy against Parkinson’s disease.

The challenge now is to translate these scientific advances into widely accessible therapies that can be implemented in clinical practice. Public awareness campaigns and education about the importance of circadian health in neurodegeneration could empower patients and caregivers to adopt lifestyle changes conducive to circadian alignment. Ultimately, a holistic approach that merges pharmacological, behavioral, and technological interventions addressing the circadian clock may transform the landscape of Parkinson’s disease management.

In conclusion, the circadian clock sits at a crossroads of neurological health and disease, embodying a complex regulator whose dysfunction in Parkinson’s disease disrupts fundamental biological rhythms. The elucidation of this relationship heralds a new era where time itself becomes a therapeutic target, offering hope for improved outcomes through synchronizing internal clocks with restorative, evidence-based treatments. The continued unraveling of these mechanisms holds not only promise but imperative for addressing the unmet challenges in Parkinson’s disease.

Subject of Research: Circadian clock dysfunction mechanisms and therapeutic strategies in Parkinson’s disease.

Article Title: Circadian clock dysfunction in Parkinson’s disease: mechanisms, consequences, and therapeutic strategy.

Article References:
Yalçin, M., Grande, V., Outeiro, T.F. et al. Circadian clock dysfunction in Parkinson’s disease: mechanisms, consequences, and therapeutic strategy. npj Parkinsons Dis. 11, 213 (2025). https://doi.org/10.1038/s41531-025-01009-9

Image Credits: AI Generated